New Directions in the Treatment of Thyroid Cancer

Journal of the American College of Surgeons

Volumn 205, Issue 4 SUPPL., 2007, Pages

  You, Y Nancy ^a   Lakhani, Vipul ^a   Wells Jr , Samuel A ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CALCITONIN; CEP 701; CEP 751; FR 901228; GEFITINIB; IMATINIB; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; ROSIGLITAZONE; SORAFENIB; VANDETANIB;

ADVANCED CANCER; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; GENE MUTATION; GENOTYPE; HUMAN; LYMPHADENECTOMY; MORBIDITY; ONCOGENE RET; PARATHYROID TRANSPLANTATION; PRIORITY JOURNAL; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT INDICATION; TREATMENT OUTCOME;

CARCINOMA, MEDULLARY; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 34748833963     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.06.323     Document Type: Article

References (30)

1. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86 (2001) 5658-5671
2. Carlson K.M., Dou S., Chi D., et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci U S A 91 (1994) 1579-1583
3. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2 (1993) 851-856
4. Mulligan L.M., Kwok J.B., Healey C.S., et al. Germline mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
5. Frilling A., Weber F., Tecklenborg C., and Broelsch C.E. Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene. Langenbecks Arch Surg 388 (2003) 17-26
6. Lips C.J., Landsvater R.M., Hoppener J.W., et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 331 (1994) 828-835
7. Wells Jr. S.A., Chi D.D., Toshima K., et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 220 (1994) 237-247 discussion 247-250
8. Skinner M.A., Moley J.A., Dilley W.G., et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353 (2005) 1105-1113
9. Lallier M., St-Vil D., Giroux M., et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg 33 (1998) 846-848
10. Sanso G.E., Domene H.M., Garcia R., et al. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers. Cancer 94 (2002) 323-330
11. van Heurn L.W., Schaap C., Sie G., et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg 34 (1999) 568-571
12. Dralle H., Gimm O., Simon D., et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 22 (1998) 744-750 discussion 750-741
13. Niccoli-Sire P., Murat A., Baudin E., et al., The French Calcitonin Tumours Study Group (GETC). Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. Eur J Endocrinol 141 (1999) 468-474
14. Rodriguez G.J., Balsalobre M.D., Pomares F., et al. Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. J Am Coll Surg 195 (2002) 159-166
15. Ukkat J., Lorenz K., Hinze R., et al. Importance of early screening and prophylactic thyroidectomy in asymptomatic nonindex RET germline carriers. World J Surg 25 (2001) 713-717
16. Pacini F., Romei C., Miccoli P., et al. Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations. Surgery 118 (1995) 1031-1035
17. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 (1996) 1575-1579
18. Olson Jr. J.A., DeBenedetti M.K., Baumann D.S., and Wells Jr. S.A. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. Ann Surg 223 (1996) 472-478 discussion 478-480
19. Santoro M., Melillo R.M., Carlomagno F., et al. Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci 963 (2002) 116-121
20. Eng C., Mulligan L.M., Smith D.P., et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 12 (1995) 209-212
21. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 12 (2005) 245-262
22. Cuccuru G., Lanzi C., Cassinelli G., et al. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN 2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96 (2004) 1006-1014
23. Strock C.J., Park J.I., Rosen D.M., et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91 (2006) 79-84
24. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62 (2002) 7284-7290
25. Heymack J. ZD6474-Clinical experience to date. Br J Cancer 92 (2005) S14-S20
26. Clinical trials in thyroid cancer (2006). http://www.clinicaltrials.gov/ct/search;jsessionid=EDA999DA72483FD20768237C6CE9B310?term=thyroid+cancer Availabl at: http://www.clinicaltrials.gov/ct/search;jsessionid=EDA999DA72483FD20768237C6CE9B310?term=thyroid+cancer. Accessed: March 23
27. Ratain M., Flaherty K., Stadler W., et al. Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial. ASCO Meeting Abstracts 22 (2004) 4501
28. Kloos R., Ringel M., Knopp M., et al. Preliminary results of phase II study of RAF/VEGF-R kinase inhibitor, BAY 43-9006 (Sorafenib), in metastatic thyroid carcinoma (2006). http://www.13itc.org/abstracts/oral/o61.htm Available at: http://www.13itc.org/abstracts/oral/o61.htm. Accessed: March 31
29. Carlomagno F., Anaganti S., Guida T., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98 (2006) 326-334
30. Shen W.T., and Chung W.Y. Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists. Thyroid 15 (2005) 594-599